Floatz logo

lutetium (<sup>177</sup>Lu) zadavotide guraxetan

Metastatic Castration-Resistant Prostate Cancer

Jonsson Comprehensive Cancer CenterOtherPhase 3Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
65/ 100

Competitive context

251 Active assets in the Metastatic Castration-Resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

lutetium (<sup>177</sup>Lu) zadavotide guraxetan is also rated in:

metastatic prostate carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →